PB2035 ISAVUCONAZOLE AS PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN STEM CELL TRANSPLANT PATIENTS: A DESCRIPTIVE SINGLE CENTER EXPERIENCE.

Abstract

Background:Isavuconazole is a novel triazole antifungal approved for treating invasive aspergillosis and mucormycosis with predictable pharmacokinetics compared to its counterparts; the handling of interactions with other medications is easier, which is the most important advantage of this antifungal. The aim of our study is to describe the experience with this Triazole in prophylaxis in our hospital.Aims:The aim of this study its to describe our experiencie with Isovuconazole.Methods:A retrospective review from the patients undergoing allogenic stem cell transplantation who received Isavuconazole in prophylaxis was performed. We analyze the demographic data and the risk factors related to the host, disease, treatment and the transplant.Results:From a sample of 6 patients with a main age of 52 age years, equal sex ratio, five patients have an acute myeloid leukemia (ALM) and one patient a myelodysplastic syndrome (MDS), all the patients has at least one high risk factor for the development of invasive fungal infections (IFI), described in the table 1. All of them was taking corticosteroids due to chronic/acute GVHD and one patient because of an autoimmune disease.All patients were treated with oral Isavuconazole at 200 mg per day at least 14 days for prophylaxis; the reasons to choose Isavuconazole were elevated liver transaminases in four cases and Posaconazole intolerance in two patients.Serum detection of galactomannan was performed for all patients every week during antifungal therapy and all the results were negative.Summary/Conclusion:Although the efficacy and safety of Isavuconazole, there is no indication in the technical sheet for prophylaxis with this triazole. At this time, none of our patients developed an IFI or intolerance to treatment. There are few studies that evaluate prophylaxis, most related to the experience in solid organ transplantation, but it is not known what is happening in the real world of hematological diseases. In our experience seems to be a useful and safe drug, however, more studies are needed to verify this hypothesis.image